UBS AM
TXG icon

UBS AM’s 10x Genomics TXG Stock Holding History

UBS AM’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.49M Sell
195,465
-10,072
-5% -$264K ﹤0.01% 1409
2026
Q1 		$4.36M Buy
205,537
+35,948
+21% +$719K ﹤0.01% 1631
2025
Q4 		$2.77M Buy
169,589
+21,202
+14% +$320K ﹤0.01% 1744
2025
Q3 		$1.73M Sell
148,387
-114,261
-44% -$1.49M ﹤0.01% 1813
2025
Q2 		$3.04M Sell
262,648
-6,841,120
-96% -$62.4M ﹤0.01% 1951
2025
Q1 		$62M Buy
7,103,768
+4,987,195
+236% +$62.9M 0.02% 639
2024
Q4 		$30.4M Buy
2,116,573
+193,588
+10% +$3.05M 0.01% 796
2024
Q3 		$43.4M Sell
1,922,985
-3,498
-0.2% -$72.3K 0.01% 702
2024
Q2 		$37.5M Buy
1,926,483
+1,791,802
+1,330% +$46.9M 0.01% 683
2024
Q1 		$5.05M Buy
134,681
+1,717
+1% +$75.4K ﹤0.01% 1245
2023
Q4 		$7.44M Sell
132,964
-777
-0.6% -$33.8K ﹤0.01% 1097
2023
Q3 		$5.52M Sell
133,741
-300
-0.2% -$15.6K ﹤0.01% 1172
2023
Q2 		$7.48M Hold
134,041
– – ﹤0.01% 1073
2023
Q1 		$7.48M Buy
134,041
+5,546
+4% +$259K ﹤0.01% 1073
2022
Q4 		$4.68M Sell
128,495
-1,018
-0.8% -$33.3K ﹤0.01% 1192
2022
Q3 		$3.69M Sell
129,513
-329,829
-72% -$12.6M ﹤0.01% 1307
2022
Q2 		$20.8M Sell
459,342
-95,411
-17% -$4.95M 0.01% 729
2022
Q1 		$42.2M Buy
554,753
+57,624
+12% +$5.04M 0.02% 654
2021
Q4 		$74.1M Sell
497,129
-31,151
-6% -$4.77M 0.03% 552
2021
Q3 		$76.9M Buy
528,280
+10,327
+2% +$1.77M 0.03% 509
2021
Q2 		$101M Buy
517,953
+20,239
+4% +$3.66M 0.04% 429
2021
Q1 		$90.1M Sell
497,714
-123,394
-20% -$21.3M 0.04% 453
2020
Q4 		$87.9M Buy
621,108
+180,577
+41% +$26.2M 0.04% 444
2020
Q3 		$54.9M Buy
440,531
+45,150
+11% +$4.74M 0.03% 489
2020
Q2 		$35.3M Buy
395,381
+32,389
+9% +$2.52M 0.02% 589
2020
Q1 		$22.6M Buy
362,992
+505
+0.1% +$39.4K 0.02% 643
2019
Q4 		$27.6M Buy
362,487
+177,804
+96% +$10.7M 0.02% 691
2019
Q3 		$9.31M Buy
+184,683
New +$10.2M 0.01% 977

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS AM's TXG Position: Q2 2026 in Review

UBS AM reduced its 10x Genomics (TXG) stake by 4.9% in Q2 2026, selling an estimated $264K and leaving 195,465 shares worth $7.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1409.

UBS AM first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $101M in Q2 2021. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • UBS AM held 195,465 shares of 10x Genomics worth $7.49M as of Q2 2026.
  • UBS AM sold 10,072 10x Genomics shares in Q2 2026, an estimated $264K.
  • 10x Genomics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1409 holding.
  • UBS AM first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • UBS AM's 10x Genomics position peaked at $101M in Q2 2021.
  • 391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.